Article
Biochemistry & Molecular Biology
Yiyoung Kwon, Eun-Sil Kim, Yoon-Zi Kim, Yon-Ho Choe, Mi-Jin Kim
Summary: This study aims to measure the concentration of cytokines produced during the inflammation process to investigate if there are any differences in response to treatment of pediatric Crohn's disease and to determine if the initial tumor necrosis factor-alpha (TNF-alpha) level affected the trough concentration of infliximab (IFX).
Article
Gastroenterology & Hepatology
Ken Lund, Michael Due Larsen, Torben Knudsen, Jens Kjeldsen, Rasmus Gaardskaer Nielsen, Bente Mertz Norgard
Summary: The study showed that pediatric and adolescent patients with Crohn's disease who received combination therapy of infliximab and immunomodulators had a reduced risk of intestinal surgeries and switching to another anti-TNF alpha agent compared to patients receiving infliximab alone.
JOURNAL OF CROHNS & COLITIS
(2021)
Article
Nutrition & Dietetics
Sheng-long Xia, Quan-jia Min, Xiao-xiao Shao, Dao-po Lin, Guo-long Ma, Hao Wu, Shu-guang Cao, Yi Jiang
Summary: The study found that vitamin D3 supplementation can improve the effectiveness of IFX treatment in CD patients, especially for those with vitamin D3 deficiency.
FRONTIERS IN NUTRITION
(2021)
Article
Gastroenterology & Hepatology
Ping Zhu, Jin-fang Sun, Yun-fei Gu, Hong-jin Chen, Min-min Xu, You-ran Li, Bo-lin Yang
Summary: This retrospective cohort study aimed to determine the long-term efficacy of early initiation of infliximab following surgery among PFCD patients. The results showed no clear benefit between early and delayed infliximab induction groups in terms of surgical re-intervention and fistula healing.
BMC GASTROENTEROLOGY
(2022)
Article
Gastroenterology & Hepatology
Raphael P. Luber, Luke Dawson, Stephanie Munari, Viraj C. Kariyawasam, Catherine Martin, Peter R. Gibson, Miles P. Sparrow, Mark G. Ward
Summary: Combination therapy with optimized thiopurines was superior to infliximab monotherapy in inducing and maintaining response in the first 6 months in Crohn's disease. However, there was no clinical advantage to combination therapy in maintenance beyond the initial period, suggesting individualized consideration for thiopurine withdrawal. Therapeutic TGN levels were associated with higher remission rates and improved outcomes in Crohn's disease treatment.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Chen Yueying, Feng Jing, Feng Qi, Shen Jun
Summary: A magnetic resonance enterography-based model was constructed in this study to predict the risk of loss of response to infliximab (IFX) in bio-naive patients with Crohn's disease (CD), providing an effective tool for the early estimation of treatment response before biological intervention.
EUROPEAN RADIOLOGY
(2023)
Article
Gastroenterology & Hepatology
Xavier Roblin, Pauline Veyrard, Laetitia Bastide, Anne E. Berger, Mathilde Barrau, Anne-Sophie Paucelle, Louis Waeckel, Sany Kwiatek, Bernard Flourie, Stephane Nancey, Stephane Paul
Summary: This study aimed to investigate the intra-individual variations of IFX drug levels in Crohn's disease patients during two consecutive cycles of maintenance therapy with CT-P13 sc. The results showed that IFX drug levels were quite stable within the 14-day treatment cycle, and therapeutic drug monitoring of IFX can be performed at any time between two CT-P13 sc injections in patients with inactive CD.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Gastroenterology & Hepatology
Gilles Boschetti, Maria Nachury, David Laharie, Xavier Roblin, Cyrielle Gilletta, Alexandre Aubourg, Arnaud Bourreille, Camille Zallot, Xavier Hebuterne, Anthony Buisson, Jean-Charles Grimaud, Yoram Bouhnik, Matthieu Allez, Romain Altwegg, Stephanie Viennot, Lucine Vuitton, Franck Carbonnel, Stephane Paul, Kristell Desseaux, Jerome Lambert, Laurent Peyrin-Biroulet
Summary: This study aimed to investigate the efficacy and safety of infliximab (IFX) reintroduction in Crohn's disease (CD) after discontinuation due to loss of response or intolerance. The results showed that IFX retreatment was effective and safe in approximately one-third of patients with CD, regardless of the reason for prior discontinuation. Early detection of anti-drug antibodies could predict subsequent failure of IFX reintroduction and infusion reactions.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2022)
Article
Medicine, General & Internal
Hee Man Kim, Jin Woo Kim, Hyun-Soo Kim, Joo Sung Kim, You Sun Kim, Jae Hee Cheon, Won Ho Kim, Byong Duk Ye, Won Moon, Sung Hee Jung, Young-Ho Kim, Dong Soo Han
Summary: This study in Korean patients with Crohn's disease found a significant association between the use of azathioprine/6-MP and TNF-alpha antagonists and a reduced risk of abdominal and perianal surgery.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Biochemistry & Molecular Biology
Yoon-Zi Kim, Ben Kang, Eun-Sil Kim, Yiyoung Kwon, Yon-Ho Choe, Mi-Jin Kim
Summary: This study compared the efficacy and immunogenicity of methotrexate (MTX) and azathioprine (AZA) as concurrent therapies for pediatric Crohn's disease (CD). The results showed that there were no significant differences in remission rates between the two medications, and they both effectively maintained adequate Infliximab (IFX) levels and reduced anti-drug antibody (ADA) production.
Article
Pharmacology & Pharmacy
Erwin Dreesen, Sophie Berends, David Laharie, Geert D'Haens, Severine Vermeire, Ann Gils, Ron Mathot
Summary: Evidence for the benefits of pharmacokinetic (PK) and pharmacodynamic (PD) monitoring of infliximab in patients with Crohn's disease (CD) remains scarce. By developing a population (pop)PK/PD model, the study aimed to characterize the infliximab dose-exposure-biomarker-response relationship. Results showed that infliximab clearance and baseline fCal were influenced by various factors, with large interpatient PK and PD variability resulting in a flat dose-response curve. Model-informed dose optimization may improve the effectiveness of infliximab therapy.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2021)
Article
Gastroenterology & Hepatology
Ohad Atia, Noa Asayag, Gili Focht, Rona Lujan, Oren Ledder, Shira Greenfeld, Revital Kariv, Iris Dotan, Hagit Gabay, Ran Balicer, Ziona Haklai, Daniel Nevo, Dan Turner
Summary: This population-based study explores perianal involvement in Crohn's disease and compares the disease course between severe and non-severe perianal CD. The study finds that perianal CD patients are more likely to be hospitalized, undergo surgery, and develop anorectal cancer, with worse outcomes observed in severe perianal CD.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Neeraj Narula, Emily C. L. Wong, Parambir S. Dulai, Neil K. Sengupta, John K. Marshall, Jean-Frederic Colombel, Walter Reinisch
Summary: This post hoc analysis suggests that infliximab and ustekinumab have similar efficacy and speed of onset in biologic-naive patients with CD.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Immunology
Chenglin Ye, Sizhe Zhu, Jingping Yuan
Summary: This study analyzed the gene expression profiles of patients with Crohn's disease (CD) and identified two gene subtypes: immune and metabolic. The immune subtype was associated with leukocyte migration and cytokine interactions, while the metabolic subtype was associated with metabolic pathways. The combination of interleukin 1 beta, interleukin 6, and Toll-like receptor 4 effectively distinguished between these two gene subtypes.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Gastroenterology & Hepatology
Yizhong Wang, Xuefeng Gao, Xinyue Zhang, Fangfei Xiao, Hui Hu, Xiaolu Li, Fang Dong, Mingming Sun, Yongmei Xiao, Ting Ge, Dan Li, Guangjun Yu, Zhanju Liu, Ting Zhang
Summary: The study revealed that pediatric CD patients have gut microbial dysbiosis and altered metabolism after IFX therapy, which is related to treatment outcomes. The effects of IFX treatment may be mediated by enriching bacteria taxa that produce SCFAs and BSH, thereby inhibiting inflammation and restoring bile acid metabolism. Some fecal bacteria and metabolites may serve as predictors of IFX therapy outcomes for pediatric CD patients.
